CoChat

Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model

Open access

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 18 of the 37 sources its claims cite were checked for support.

Abstract

High Resolution Image Download MS PowerPoint Slide The development of nanoparticle-based targeted therapeutics for the treatment of cancer requires a well-defined understanding of the tumor microenvironment, which is challenging due to tumor complexity and heterogeneity. Recent advancements in three-dimensional (3D) cell models such as tumor-on-a-chip devices can overcome some of these challenges by providing coculture in vitro systems (tumor surrounded by tubular endothelial cells) that mimic native cellular environments to accurately study the enhanced permeability and retention (EPR) potential of drug delivery systems under flow conditions. However, inducing “leaky” vasculature in endothelial cells surrounding solid tumors in microfluidic devices is not readily controllable and highly dependent on tumor cell identity. Utilizing a microfluidic tumor model (MTM) consisting of a tumor region surrounded by a 3D microvascular network, we have simulated the EPR effect by activating a known regulator of endothelial junction formation and edema: the transient receptor potential vanilloid 4 (TRPV4) ion channel, to rapidly assess extravasation and tumor accumulation of nanoparticles of different sizes and surface chemistries. Treatment with a selective TRPV4 agonist stimulated reorganization of the actin cytoskeleton and disruption of adherens junctions to provide a concentration-dependent or “tunable” leakiness, confirmed by increased tumor uptake of fluorescent dextran macromolecular tracers from the vascular channels. Although this controlled 3D in vitro vascular-edema system may not exemplify all of the complexities of edema mechanisms in vivo, it provides a rapid, materials-focused screening method to assess the extravasation and tumor uptake potential of nanoparticles with distinct properties. We show that the passage of nanoparticles through leaky vasculature is not solely governed by particle size but also by surface chemistry, where surface tertiary amines limit tumor cell association due to unwanted endothelial interactions.

Overview

CoChat Summary

## TL;DR

This paper presents a microfluidic tumor-on-a-chip model in which TRPV4 activation was used to tune endothelial leakiness and rapidly screen nanoparticle extravasation into tumors. In this system, 40 nm carboxylated nanoparticles showed the greatest tumor penetration, and surface chemistry also affected endothelial association, with tertiary amines increasing endothelial interactions.

## Key findings

  • The vascularized microfluidic tumor model had a tumor compartment separated from a branched endothelial network by a 2 μm porous interface.
  • TRPV4 agonist GSK101 increased endothelial leakiness in a concentration-dependent way: 1, 3, and 10 nM reduced VE-cadherin detection, increased endothelial gaps, and altered F-actin organization.
  • In the dextran assay, nonstimulated conditions gave 22.15% fluorescence distribution for FD4 (4 kDa) and 6.22% for RD70 (70 kDa) in the tumor area; with GSK101, uptake increased, with 3 nM considered permissive for 70 kDa macromolecule passage.
  • For nanoparticles, 40 nm carboxylic acid particles had the greatest tumor penetration and endothelial/tumor cell association, and 70 nm tertiary amine particles associated more strongly with HUVECs than 70 nm carboxylic acid particles.
  • With 3 nM GSK101, nanoparticle extravasation into the tumor increased for all three sizes tested, with a significant increase in MDA-MB-231 cell association and no effect on HUVEC association; the paper also reports 2-fold higher FD4 and 3-fold higher RD70 extravasation.

## Methods

  • The study used a SynVivo microfluidic tumor model with MDA-MB-231 breast cancer cells in the tumor compartment and HUVECs in a surrounding 3D vascular network under continuous flow.
  • Endothelial barrier leakiness was induced with the TRPV4 agonist GSK1016790A at 1, 3, or 10 nM, and permeability was assessed using FITC-dextran 4 kDa and rhodamine dextran 70 kDa.
  • Nanoparticle screening used Cy5-labeled polymer nanoparticles of approximately 40, 70, and 130 nm, plus 70 nm particles with carboxylic acid or tertiary amine surface groups; analysis combined confocal microscopy and flow cytometry.

## Limitations

  • The paper states that the model “could not fully represent the complexity of biological systems”, specifically noting the lack of plasma proteins and circulating blood cells that affect nanoparticle properties and nanobio interactions.
  • The authors note that HUVECs may not entirely recapitulate all known roles for TRPV4 in tumor vasculature.
  • They also say the use of variable flow rates and comparisons with straight-channel devices remain only a theoretical advantage until more rigorous analyses are done.
  • Evident from the text: the work is a proof-of-concept in vitro study, so its findings are not direct in vivo validation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1021/acsanm.8b02056

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

9 Valid · 1 Not valid · 4 Not checked · 47 Own results and interpretations

24 more claims

Create a free account to see all 61 claims and to verify the 6 references still open.

See all claims — free account
  • Probably not a substantial claim. 9
  • It may state two separate claims as one. 26
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 72 references

Cited by

See all 52

Metadata

Authors
Vu, M. N., Rajasekhar, P., Poole, D. P., Khor, S. Y., Truong, N. P., Nowell, C. J., Quinn, J. F., Whittaker, M., Veldhuis, N. A., & Davis, T. P.
Affiliations
  • Hanoi University of Pharmacy (VN)
  • Australian Research Council (AU)
  • Monash University (AU)
  • University of Warwick (GB)
Corresponding author
  • Veldhuis, Nicholas A.
  • Davis, Thomas P.
Venue
ACS Applied Nano Materials
Published
2019-03-29
Volume
2
Issue
4
Pages
1844-1856
ISSN
2574-0970 (ISSN-L)
OpenAlex
W2927037977
Cited by
52
References
72
Citations by year
2026: 6 · 2025: 2 · 2024: 8 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 6 · 2019: 1
FWCI
1.92
Type
journal article
Language
en
Open access
Locations
  • ACS Applied Nano Materials (publishedVersion, other-oa)
  • Monash University Research Portal (Monash University) (submittedVersion, other-oa)
  • Warwick Research Archive Portal (University of Warwick) (submittedVersion)
Funders
  • Takeda Pharmaceuticals U.S.A. (NA)
  • Australian Research Council (DE180100076, FL140100052)
  • Department of Education and Training (NA)
  • Centre of Excellence in Convergent Bio-Nano Science and Technology, Australian Research Council (CE140100036)
  • Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (NA)
  • Government of Vietnam (NA)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
nanoparticle extravasation, tumor-on-a-chip, microfluidic tumor model, enhanced permeability and retention effect, adherens junctions, actin cytoskeleton, tumor microenvironment, nanoparticle surface chemistry, nanoparticle size, tumor accumulation, edema, targeted cancer drug delivery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model. https://app.cochat.ai/papers/10.1021/acsanm.8b02056
The paper
Vu, M. N., Rajasekhar, P., Poole, D. P., Khor, S. Y., Truong, N. P., Nowell, C. J., Quinn, J. F., Whittaker, M., Veldhuis, N. A., & Davis, T. P. (2019). Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model. ACS Applied Nano Materials. https://doi.org/10.1021/acsanm.8b02056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.